• News / Press
  • Contact
Arcutis Biotherapeutics Logo
  • Who We Are
    • Vision
    • Leadership
    • Board of Directors
    • Scientific Advisors
    • Strategic Collaborations
  • Our Focus
    • Plaque Psoriasis
    • Atopic Dermatitis
    • Seborrheic Dermatitis
    • Scalp Psoriasis
    • Hand Eczema
    • Vitiligo
    • Alopecia Areata
  • Pipeline
    • Topical Roflumilast Cream (ARQ-151)
    • Topical Roflumilast Foam (ARQ-154)
    • ARQ-252
    • ARQ-255
  • Clinical Programs
    • Clinical Trials
    • Scientific Publications
  • Investors
Arcutis Biotherapeutics Logo
bubble image

News / Press

ARQ-151 Plaque Psoriasis Program

Posted on May 7, 2019 by ArqAdmin - Press Releases

ARQ-151-Plaque-Psoriasis-Program
Download

Recent Posts

  • Arcutis Announces ARQ-154 Program for Scalp Psoriasis and Enrollment of First Patient in Phase 2b Clinical Trial
  • Patricia Turney Joins Arcutis as Senior Vice President, Manufacturing
  • Arcutis Announces Exercise of Option for Exclusive License to Highly Selective JAK1 Inhibitor for All Topical Dermatological Uses in U.S., Canada, Europe and Japan
  • Arcutis Announces Enrollment of First Patients in Two Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 as a Potential Once Daily Topical Treatment for Plaque Psoriasis
  • Arcutis Biotherapeutics Announces Filing of Registration Statement for Proposed Initial Public Offering

Archives

  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019

Categories

  • Press Releases
Arcutis Biotherapeutics Logo
805.418.5006
information@arcutis.com
  • linkedin
  • Who We Are
  • Our Focus
  • Pipeline
  • Clinical Trials
  • Investors
  • Contact
  • News / Press
  • Legal Disclaimer
  • Careers

© 2020 Arcutis Biotherapeutics

Designed By Watermark